GeoVax Labs Stock Continues To Surge: What's Going On?

$GeoVax Labs (GOVX.US)$ shares have surged over 225% in the past week, continuing to rally Monday. This spike comes after the World Health Organization (WHO) declared a public health emergency due to an mpox outbreak in Africa. The WHO's concern over the rapid spread of a new mpox clade in the region has prompted calls for an international response.

GeoVax, a clinical-stage biotech company, is focused on developing immunotherapies and vaccines for cancers and infectious diseases. The company has previously published research suggesting its vaccines may help prevent mpox.

EF Hutton analyst Jason Kolbert has maintained a Buy rating for GeoVax with a price target of $18. GeoVax is also set to present at the Emerging Growth Conference, where investors will have the chance to interact with the company's CEO, David Dodd.